HOWL Stock Price, Werewolf Therapeutics, . Quote, Chart

Market Summary

USD4.72-0.16

Market Closed

-3.28%

HOWL Stock Price

View Fullscreen

HOWL RSI Chart

HOWL Valuation

Market Cap

205.1M

Price/Earnings (Trailing)

-4.93

Price/Sales (Trailing)

10.26

Price/Free Cashflow

-5.3

HOWL Price/Sales (Trailing)

HOWL Profitability

Return on Equity

-35.36%

Return on Assets

-23.41%

Free Cashflow Yield

-18.88%

HOWL Fundamentals

HOWL Revenue

Revenue (TTM)

20.0M

Rev. Growth (Yr)

-79.35%

Rev. Growth (Qtr)

-74.5%

HOWL Earnings

Earnings (TTM)

-41.6M

Earnings Growth (Yr)

-35.14%

Earnings Growth (Qtr)

-34.91%

Breaking Down HOWL Revenue

Last 7 days

-6.5%

Last 30 days

-19.2%

Last 90 days

-31.5%

Trailing 12 Months

73.5%

How does HOWL drawdown profile look like?

HOWL Financial Health

Current Ratio

6.71

HOWL Investor Care

Shares Dilution (1Y)

22.03%

Diluted EPS (TTM)

-1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	20.9M	24.8M	25.8M	20.0M
2022	4.2M	8.3M	12.3M	16.4M
2021	77.3K	91.5K	105.8K	120.0K
2020	0	0	0	63.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Werewolf Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 06, 2023	ra capital management, l.p.	bought	4,095,130	2.21	1,853,000	-
Jan 12, 2022	seidel-dugan cynthia	acquired	111,838	2.81488	39,731	chief scientific officer
Dec 30, 2021	leonard reid	acquired	21,999	1.56	14,102	chief operating officer
Dec 15, 2021	leonard reid	sold	-40,241	13.4139	-3,000	chief operating officer
Jun 16, 2021	ra capital management, l.p.	bought	124,140	13.37	9,285	-
Jun 15, 2021	ra capital management, l.p.	bought	103,056	12.95	7,958	-
Jun 14, 2021	ra capital management, l.p.	bought	3,902,200	12.75	306,055	-
May 04, 2021	longwood fund iii gp, llc	bought	4,000,000	16.00	250,000	-
May 04, 2021	mpm bioventures 2014, l.p.	acquired	-	-	3,062,240	-
May 04, 2021	lazarus alon	acquired	-	-	1,646,640	-

Which funds bought or sold HOWL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	985	962,904	1,018,820	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	26.12	632,781	1,199,180	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	222,925	551,357	0.01%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	1,119,700	1,119,700	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-85.72	-63,162	19,913	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	new	-	10,921,700	10,921,700	0.01%
May 15, 2024	STATE STREET CORP	reduced	-14.74	138,983	461,169	-%
May 15, 2024	MORGAN STANLEY	added	3,329	131,036	133,352	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-10.26	4,098,740	12,189,600	-%

Are Funds Buying or Selling HOWL?

Are funds buying HOWL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HOWL

No. of Funds

Unveiling Werewolf Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 07, 2024	ra capital management, l.p.	14.2%	6,192,881	SC 13D/A
Feb 14, 2024	ra capital management, l.p.	15.2%	6,179,035	SC 13D/A
Feb 14, 2024	pfm health sciences, lp	9.6%	6	SC 13G/A
Feb 13, 2024	bank of america corp /de/	5.8%	2,096,081	SC 13G
Feb 12, 2024	rubric capital management lp	5.35%	1,935,357	SC 13G/A
Dec 21, 2023	adage capital partners gp, l.l.c.	8.38%	3,034,255	SC 13G
Feb 10, 2023	rubric capital management lp	5.97%	1,835,387	SC 13G
Jan 17, 2023	pfm health sciences, lp	4.2%	6	SC 13G/A
Jan 17, 2023	pfm health sciences, lp	5.3%	6	SC 13G
Jan 10, 2023	ra capital management, l.p.	17.96%	6,159,054	SC 13D/A

Recent SEC filings of Werewolf Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	SC 13D/A	13D - Major Acquisition
May 03, 2024	8-K	Current Report
May 03, 2024	10-Q	Quarterly Report
Apr 12, 2024	DEFA14A	DEFA14A
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	ARS	ARS
Mar 07, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	8-K	Current Report
Mar 07, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Werewolf Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Werewolf Therapeutics, Inc. News

Latest updates

Werewolf Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-100.0%	-	1,504	5,897	8,081	4,500	7,283	4,970	4,148	2,082	15.00	37.00	51.00	17.00	19.00	22.00	24.00	67.00
Operating Expenses	23.8%	17,904	14,463	15,148	14,148	16,687	20,462	17,509	19,120	15,366	17,884	13,795	10,956	7,452	7,392	6,053	5,065	3,894
S&GA Expenses	-100.0%	-	4,814	4,310	4,565	4,981	4,603	4,439	5,233	4,421	4,484	4,008	3,691	2,635	2,106	1,241	1,285	1,131
R&D Expenses	33.8%	12,908	9,649	10,838	9,583	11,706	15,859	13,070	13,887	10,945	13,400	9,787	7,265	4,817	5,286	4,812	3,780	2,763
Interest Expenses	-39.0%	910	1,493	904	742	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-34.9%	-16,193	-12,003	-8,285	-5,098	-11,982	-11,930	-11,943	-14,594	-15,343	-17,869	-13,758	-10,921	-7,435	-7,402	-6,068	2,257	-3,827
Net Income Margin	-11.3%	-2.08*	-1.87*	-1.45*	-1.65*	-2.41*	-3.28*	-4.85*	-7.45*	-13.82*	-416.52*	-373.67*	-347.83*	-241.40*	-238.73*	-	-	-
Free Cashflow	-222.1%	-15,408	-4,783	-7,429	-11,103	-10,066	-12,388	-16,426	-1,414	-13,979	-12,945	-12,519	-10,571	-7,339	-6,018	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	1.6%	178	175	176	185	195	160	172	175	165	179	178	190	89.00	96.00
Current Assets	2.8%	142	138	139	147	157	140	152	154	145	161	174	186	85.00	93.00
Cash Equivalents	19.4%	160	134	130	137	148	129	140	146	144	159	172	185	85.00	93.00
Net PPE	-5.4%	8.00	8.00	8.00	8.00	9.00	9.00	9.00	9.00	6.00	3.00	1.00	1.00	1.00	1.00
Liabilities	-5.4%	60.00	63.00	64.00	67.00	74.00	38.00	41.00	45.00	25.00	26.00	9.00	9.00	7.00	7.00
Current Liabilities	9.5%	21.00	19.00	14.00	15.00	22.00	24.00	28.00	30.00	11.00	12.00	8.00	7.00	5.00	5.00
Shareholder's Equity	5.6%	118	111	112	119	121	122	131	130	139	153	169	182	-	-
Retained Earnings	-4.7%	-360	-344	-332	-323	-318	-306	-294	-282	-268	-252	-235	-221	-153	-51.86
Additional Paid-In Capital	4.9%	478	455	445	442	440	429	426	413	408	406	404	403	-	-
Shares Outstanding	10.7%	43.00	39.00	36.00	36.00	35.00	31.00	30.00	28.00	27.00	27.00	27.00	18.00	1.00	-
Float	-	-	-	-	67.00	-	-	-	59.00	-	-	-	202	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-233.6%	-15,297	-4,585	-7,208	-10,921	-9,898	-11,870	-14,472	-303	-13,951	-12,673	-12,417	-10,460	-7,326	-6,009	-4,921	-4,295	-3,399
Share Based Compensation	23.1%	2,305	1,873	2,097	1,930	2,108	1,942	1,936	1,777	1,745	1,296	1,479	781	539	221	133	221	57.00
Cashflow From Investing	43.9%	-111	-198	-221	-182	-168	-518	-1,954	-1,111	-28.00	-272	-102	-111	-13.00	-9.00	-57.00	-45.00	-449
Cashflow From Financing	123.3%	20,259	9,073	41.00	692	48,623	1,256	11,076	3,415	159	38.00	-276	110,203	-538	71,880	-97.00	22,074	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HOWL Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Collaboration revenue	$ 742	$ 4,464
Operating expenses:
Research and development	12,908	11,706
General and administrative	4,996	4,981
Total operating expenses	17,904	16,687
Operating loss	(17,162)	(12,223)
Other income:
Interest income	1,973	1,519
Interest expense	(1,003)	(172)
Other expense, net	(1)	(1,106)
Total other income	969	241
Net loss	$ (16,193)	$ (11,982)
Net loss per share attributable to common stockholders, basic and diluted
Net loss per common share, basic (in usd per share)	$ (0.39)	$ (0.34)
Net loss per common share, diluted (in usd per share)	$ (0.39)	$ (0.34)
Weighted-average common shares outstanding, basic and diluted
Weighted-average common shares outstanding, basic (in shares)	41,607,279	34,784,682
Weighted -average common shares outstanding, diluted (in shares)	41,607,279	34,784,682

HOWL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 139,189	$ 134,343
Prepaid expenses and other current assets	2,320	2,677
Other receivables	775	1,350
Total current assets	142,284	138,370
Property and equipment, net	7,529	7,958
Restricted cash and cash equivalents, net of current portion	21,027	21,023
Operating lease right of use asset	6,512	6,888
Other assets	248	594
Total assets	177,600	174,833
Current liabilities:
Accounts payable	1,594	1,336
Accrued expenses and other current liabilities	6,215	8,860
Operating lease liability, current	1,236	1,608
Deferred revenue, current	502	907
Note payable, current	11,667	6,667
Total current liabilities	21,214	19,378
Operating lease liability, net of current portion	10,620	10,992
Deferred revenue, net of current portion	431	433
Note payable, net of discount, issuance costs, and current portion	27,748	32,656
Total liabilities	60,013	63,459
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 43,282,371 and 39,107,048 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	477,849	455,443
Accumulated deficit	(360,266)	(344,073)
Total stockholders’ equity	117,587	111,374
Total liabilities and stockholders’ equity	$ 177,600	$ 174,833

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Daniel J. Hicklin Ph.D.
WEBSITE	https://werewolftx.com
INDUSTRY	Biotechnology
EMPLOYEES	48

Werewolf Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Werewolf Therapeutics, Inc.? What does HOWL stand for in stocks?

HOWL is the stock ticker symbol of Werewolf Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Werewolf Therapeutics, Inc. (HOWL)?

As of Fri May 17 2024, market cap of Werewolf Therapeutics, Inc. is 205.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOWL stock?

You can check HOWL's fair value in chart for subscribers.

What is the fair value of HOWL stock?

You can check HOWL's fair value in chart for subscribers. The fair value of Werewolf Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Werewolf Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HOWL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Werewolf Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether HOWL is over valued or under valued. Whether Werewolf Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Werewolf Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOWL.

What is Werewolf Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HOWL's PE ratio (Price to Earnings) is -4.93 and Price to Sales (PS) ratio is 10.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOWL PE ratio will change depending on the future growth rate expectations of investors.